These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 34975317)

  • 21. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
    Okamoto K; Miyoshi K; Murawaki Y
    PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.
    Ravichandra A; Bhattacharjee S; Affò S
    Adv Cancer Res; 2022; 156():201-226. PubMed ID: 35961700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
    Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
    Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells.
    Thongchot S; Ferraresi A; Vidoni C; Loilome W; Yongvanit P; Namwat N; Isidoro C
    Cancer Lett; 2018 Aug; 430():160-171. PubMed ID: 29802929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
    Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
    Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma.
    Toshida K; Itoh S; Harada N; Morinaga A; Yugawa K; Tomiyama T; Kosai-Fujimoto Y; Tomino T; Kurihara T; Nagao Y; Morita K; Oda Y; Yoshizumi T
    Cancer Sci; 2023 Mar; 114(3):937-947. PubMed ID: 36369960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28.
    Chen B; Sang Y; Song X; Zhang D; Wang L; Zhao W; Liang Y; Zhang N; Yang Q
    Theranostics; 2021; 11(8):3932-3947. PubMed ID: 33664871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma
    Sungwan P; Kidoikhammouan S; Thonsri U; Saengboonmee C; Wongkham S; Okada S; Seubwai W
    In Vivo; 2024; 38(5):2284-2293. PubMed ID: 39187317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exosome-mediated transfer of miR-93-5p from cancer-associated fibroblasts confer radioresistance in colorectal cancer cells by downregulating FOXA1 and upregulating TGFB3.
    Chen X; Liu J; Zhang Q; Liu B; Cheng Y; Zhang Y; Sun Y; Ge H; Liu Y
    J Exp Clin Cancer Res; 2020 Apr; 39(1):65. PubMed ID: 32293494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knockdown of cullin 3 inhibits progressive phenotypes and increases chemosensitivity in cholangiocarcinoma cells.
    Pratummanee K; Kerdkumthong K; Roytrakul S; Tantimetta P; Runsaeng P; Saeheng S; Obchoei S
    Mol Med Rep; 2024 Nov; 30(5):. PubMed ID: 39239747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models.
    Awasthi N; Darman L; Schwarz MA; Schwarz RE
    J Cell Mol Med; 2024 Sep; 28(17):e18585. PubMed ID: 39223878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabidiol exhibits potent anti-cancer activity against gemcitabine-resistant cholangiocarcinoma via ER-stress induction in vitro and in vivo.
    Pongking T; Thongpon P; Intuyod K; Klungsaeng S; Thanan R; Chaidee A; Charoenram N; Kongsintaweesuk S; Sakonsinsiri C; Vaeteewoottacharn K; Pinlaor S; Pinlaor P
    BMC Complement Med Ther; 2024 Aug; 24(1):325. PubMed ID: 39215312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer.
    Hu JL; Wang W; Lan XL; Zeng ZC; Liang YS; Yan YR; Song FY; Wang FF; Zhu XH; Liao WJ; Liao WT; Ding YQ; Liang L
    Mol Cancer; 2019 May; 18(1):91. PubMed ID: 31064356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway.
    Thongpon P; Intuyod K; Chomwong S; Pongking T; Klungsaeng S; Muisuk K; Charoenram N; Sitthirach C; Thanan R; Pinlaor P; Pinlaor S
    Sci Rep; 2024 Jul; 14(1):16059. PubMed ID: 38992159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo.
    Trakoonsenathong R; Kunprom W; Aphivatanasiri C; Yueangchantuek P; Pimkeeree P; Sorin S; Khawkhiaw K; Chiu CF; Okada S; Wongkham S; Saengboonmee C
    Sci Rep; 2024 Jun; 14(1):13726. PubMed ID: 38877189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis.
    Du H; Hou S; Zhang L; Liu C; Yu T; Zhang W
    Aging (Albany NY); 2023 May; 15(9):3759-3770. PubMed ID: 37166421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative proteomics analysis reveals possible anticancer mechanisms of 5'-deoxy-5'-methylthioadenosine in cholangiocarcinoma cells.
    Kerdkumthong K; Nanarong S; Roytrakul S; Pitakpornpreecha T; Tantimetta P; Runsaeng P; Obchoei S
    PLoS One; 2024; 19(6):e0306060. PubMed ID: 38923999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma.
    Lixin S; Wei S; Haibin S; Qingfu L; Tiemin P
    Mol Carcinog; 2020 Dec; 59(12):1371-1381. PubMed ID: 33052627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.